Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Process changes and their effect on process evaluation for viral clearance

C Marcus-Sekura1

  • 1Biotechnology Assessment Services, Inc., Rockville, MD, USA.

Developments in Biological Standardization
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma.

Transfusion·1986
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Ensuring biological product safety involves screening for viruses and using robust removal/inactivation processes. Thorough initial evaluations may prevent re-evaluating minor manufacturing changes.

Area of Science:

  • Biopharmaceutical Manufacturing
  • Viral Safety
  • Regulatory Science

Background:

  • Assessing biological product safety requires evaluating viral contaminant removal during manufacturing from cell cultures or tissues.
  • Screening starting materials and implementing effective viral inactivation processes are crucial for product safety, as seen with Factor VIII and HIV.
  • Regulatory agencies now mandate cell line screening for adventitious agents and process evaluation for tissue culture-derived products.

Purpose of the Study:

  • To discuss the challenges in evaluating viral removal/inactivation processes for biological products.
  • To explore which agents require evaluation and when process reassessment is necessary.
  • To analyze the impact of process changes on viral safety evaluations.

Main Methods:

Related Experiment Videos

  • Review of established methodologies for viral clearance and inactivation in biomanufacturing.
  • Analysis of regulatory expectations for viral safety assessment.
  • Discussion of factors influencing the need for process re-evaluation.

Main Results:

  • A combined approach of starting material screening and robust viral clearance/inactivation processes effectively ensures product safety.
  • Initial, comprehensive process evaluations demonstrating significant viral removal/inactivation can mitigate the need for re-evaluation of minor process modifications.
  • Challenges remain in defining the scope of viral agent evaluation and triggers for process reassessment.

Conclusions:

  • Rigorous viral safety strategies are essential for biological product manufacturing.
  • Proactive and thorough initial process validation can streamline ongoing safety assessments.
  • Continuous evaluation of viral safety in light of manufacturing changes is critical for public health.